INTRODUCTION
Diabetes mellitus is a multifarious metabolic disease typified by chronic hyperglycaemia featuring disturbances in carbohydrate, fat and protein metabolism (1) . The disease results from an absolute or relative deficiency in insulin secretion and/or insulin action (1) . The major classifications are Type 1 diabetes which results from an autoimmune destruction of pancreatic beta cells and Type 2 diabetes which occurs because of the body's ineffective use of insulin, also known as insulin resistance (2) .
The main objective of diabetic therapy is to reduce hyperglycaemia which lessens the incidence of morbidity and mortality (3) . Diabetic therapy involves lifestyle interventions such as proper dieting and regular exercise coupled with the use of medications such as insulin and/or oral hypoglycaemic agents (3) . Insulin and its analogs are compulsory in the management of Type 1 diabetes and may be introduced in Type 2 therapy when glycaemic control is poorly managed. Type 2 diabetic therapy involves the use of oral hypoglycaemic agents which fall into five major categories of either sulfonylureas, thiazolidinediones, meglitinides, biguanides and alpha-glucosidase inhibitors (3) .
For Type 1 diabetes, several limitations are associated with insulin therapy including ineffectiveness on oral administration, the need for constant refrigeration, and fatal hypoglycaemia in the event of excess dosage (4) . In the case of Type 2 diabetic therapy, oral anti-diabetic medications frequently lose their efficacy in a number of patients (3) and some medications can present with moderate to severe adverse effects. Sulfonylureas and meglitinides can cause hypoglycaemia and weight gain (3); thiazolidinediones are reported to increase risk of cardiovascular events and liver toxicity (3), while biguanides such as metformin commonly cause lactic acidosis (5).
The undesirable effects associated with conventional medications underlie the constant exploration for new drugs with safer profiles. Scientific studies have validated the efficacy of over 1200 plant species in the treatment of diabetes mellitus (6, 7) . Herbs used as therapy are speculated to have minimal undesirable effects and may be helpful in managing the various complications of this disease which include retinopathy, nephropathy, neuropathy and cardiovascular disease (3, 8) .
Petiveria alliacea, commonly known as guinea hen weed or anamu, is a perennial shrub which grows wildly in the South and Central American tropics, Africa and the Caribbean (9) . It belongs to the family Phytolaccaceae and is used in ethnotraditional medicine in Cuba and Jamaica for purported hypoglycaemic properties in diabetes. Various extracts and fractions of the plant have shown biological activity, namely analgesic and anti-inflammatory (10), anticancer (11), anti-microbial (12), abortive (13) and hypoglycaemic properties (14) .
The usefulness of P alliacea as a hypoglycaemic agent has not been widely studied and earlier investigations present conflicting glycaemic activity (9, 14) . Further experimental studies are required to finally establish its usefulness as a traditional anti-diabetic remedy. On this basis, the present study evaluated the hypoglycaemic activity of an aqueous and hexane extract of P alliacea in normoglycaemic and diabetic rats. The dried powdered leaves were extracted in a soxhlet apparatus with hexane for 72 hours. The mixture was concentrated using a rotary evaporator forming a thick paste/ slurry which was stored in a freezer for later use. The slurry was redistributed in mineral oil for dosing.
MATERIAL AND METHODS
The aqueous extract was prepared by boiling the powder in distilled water at a ratio 1:10 (w/v) for five to seven minutes. The mixture was filtered using a cheese cloth, concentrated and frozen before placing on the freeze dry machine. A dark green powder was produced. The powder was re-dissolved in distilled water for dosing.
Animals
Adult male Sprague Dawley rats (~350-500 g) were procured from The UWI Animal House. Animals were housed in meshed metal cages and maintained under standard temperature of 25-30°C, light and dark cycles of 12 hours. Animals were fed standard rat chow and tap water ad libitum.
Ethical approval was obtained from the University Hospital of the West Indies/University of the West Indies/ Faculty of Medical Sciences Ethics Committee. The experimental protocol conformed to the guidelines for animal care and use of the institution.
Fasted normoglycaemic model
The effects of single oral administration of aqueous and hexane extracts were assessed in fasted normoglycaemic rats at two dose levels (200 and 400 mg/kg bodyweight [bwt]) on separate days. Animals (n = 6 per group) were fasted overnight for 16 hours. Blood glucose was recorded before dosing and then at 30-minute intervals for three hours following administration. Blood was collected from the tail vein and glucose levels estimated using a test meter and test strips 
Glucose loaded normoglycaemic model
A single oral dose of aqueous and hexane extracts at two dose levels (200 and 400 mg/kg bwt) were tested in oral glucose loaded rats. Each dose was administered on separate days. The extracts were administered 15 minutes before glucose load (2 g/kg bwt); blood glucose was recorded before treatment and then at 30-minute intervals for three hours. Blood glucose estimates were done using Accu-Chek Active ® test meter and test strips. Controls received a single oral dose of glibenclamide (10 mg/kg bwt) or vehicle (1 ml/kg bwt). Each group comprised six rats.
Streptozotocin-induced diabetic model
Experimental diabetes was induced via a single intraperitoneal (ip) injection of freshly prepared streptozotocin (50 mg/kg bwt) [Sigma-Aldrich Company] in overnight fasted rats (17) . Streptozotocin was prepared in distilled water. Animals with fasting blood glucose (FBG) > 7 mmol/L were selected for a glibenclamide challenge to determine the type of diabetes induced. The animals were unresponsive to glibenclamide and were determined to be Type 1 diabetic.
The diabetic rats were divided into four groups (n = 5): group 1 was given aqueous extract (200 mg/kg bwt), group 2 was given hexane extract (400 mg/kg bwt), group 3 was a negative diabetic control given distilled water (1 ml/kg bwt) and group 4 was a positive diabetic control given insulin (Sigma-Aldrich Company) as an ip dose of 15 IU/kg bwt. Each group received a daily dose of their treatment for three weeks. The changes in blood glucose levels were recorded at the end of each week.
Statistical analysis
SPSS version 17 was the statistical software used. Results were expressed as mean ± SEM. The Student's t-test was used to determine significance between the mean of the control and treatment groups. Statistical significance was observed at p ≤ 0.05.
RESULTS

Effect of Palliacea on FBG levels in normoglycaemic rats
The aqueous (Fig. 1 ) and hexane extracts (Fig. 2) showed no significant reduction of blood glucose concentration in fasted normoglycaemic rats. The aqueous extract (400 mg/kg) caused a gradual increase in FBG (p ≤ 0.001). Glibenclamide (Fig. 3) , a reference drug, produced the expected decline in FBG (p ≤ 0.004).
Effect of P alliacea in glucose loaded normoglycaemic rats
Both aqueous (Fig. 4) and hexane extracts (Fig. 5 ) caused no significant overall improvement in glucose tolerance.
Hypoglycaemic Profiling of Petiveria alliacea in Rats Glibenclamide treated group 10 mgkg -1
Glibenclamide improved glucose tolerance (p ≤ 0.012) and also inhibited the peak seen after glucose load (Fig. 6 ).
Christie and Levy 
Effect of P alliacea on FBG in streptozotocin-induced diabetic rats
The aqueous extract (200 mg/kg bwt) caused no significant hypoglycaemic effect in streptozotocin-induced diabetic rats. Instead, blood glucose increased weekly throughout the experiment. Fasting blood glucose levels moved from 16.62 ± 2.34 mmol/L to 24.62 ± 1.66 mmol/L (p ≤ 0.048) [Fig. 7 ]. The hexane extract (400 mg/kg bwt) caused a significant reduction in FBG in diabetic rats in week 2 when compared to the diabetic control (p = 0.010). This effect, however, was not sustained as no further reduction in blood glucose was observed in week 3. Blood glucose moved from 15.44 ± 2.94 mmol/L to 18.14 ± 2.72 initially and significantly declined to 9.22 ± 2.94 by week 2. Blood glucose level gradually rose again to 15.12 ± 3.64 mmol/L at the end of week 3 (Fig. 8) . The insulin treated diabetic group showed the expected reduction in blood glucose levels. At the end of week 1, glucose levels started to decrease (p = 0.042). For weeks 2 and 3, significant reductions in glucose levels were observed: p < 0.0001 and p = 0.003, respectively (Fig. 9) . Effect of hexane extract of P alliacea on blood glucose levels in streptozotocin-induced diabetic rats. Asterisk show significant difference when compared to diabetic control given vehicle only (* p = 0.010).
Glibenclamide
DISCUSSION
The targeted screening of plant materials for anti-diabetic activity has increased globally, driven significantly by the limitations of current oral anti-diabetic agents (6). The preliminary screening of plant extracts in normoglycaemic rats is an established approach for determining glycaemic effects when there is normal pancreatic activity (18) . These studies are subsequently followed by assessment in diabetic rat models (17, 19) . This was the approach in the present study as we investigated the hypoglycaemic activity of P alliacea extracts in normal and diabetic rats. Phytochemical testing of P alliacea has revealed bioactive compounds such as coumarins, triterpenes, flavonoids (20) , cysteine sulfoxide derivatives (21, 22) , steroids, saponins, polyphenols and tannins (23) in extracts of varying polarities. Therefore, for our study, aqueous and hexane extracts were prepared to determine the potential glycaemic outcome of different compounds across varying polarities and also to remain consistent with earlier studies which have reported pharmacological activities (24) .
The current study revealed that the aqueous extract at 200 mg/kg and 400 mg/kg demonstrated no hypoglycaemic effect in a fasted rat model. Our results challenge previously reported findings by Lores and Cires Pujol (14) which showed an aqueous extract producing a 60% decline in blood glucose levels in fasted mice. It is important, however, to highlight that the contrasting glycaemic outcomes from our study versus that of Lores and Cires Pujol (14) may arise because of differences in sample preparation and conditions. The aqueous extract at 400 mg/kg caused a significant elevation of FBG (p ≤ 0.01); this effect was similar to a study by García-González et al (9) . The study reported a hyperglycaemic effect of P alliacea in mice. The results from García-González et al (9) and our work suggest that the aqueous extract of P alliacea has a hyperglycaemic profile in normoglycaemic mice and rats. A high sugar content of the extract at higher doses could explain the hyperglycaemia observed, however, further chemical analysis is required to confirm this. Additionally, the hexane extracts caused no significant reduction in blood glucose. This therefore confirmed that both extracts of P alliacea do not exhibit hypoglycaemic activity in normoglycaemic rats.
In the glucose loaded model, there was no improvement in glucose tolerance upon administration of either extract, suggesting that the extracts do not promote insulin secretion from beta cells and are unable to inhibit the peak in glucose levels.
For the diabetic studies, a single dose of each extract was selected. The lower dose of the aqueous extract was chosen because it produced the most notable response in the glucose loaded model (Fig. 4) . The higher dosage for the hexane extract was selected since it produced the most notable response in the glucose loaded model (Fig. 5) . During the diabetic study, the hexane extract (400 mg/kg) reduced glucose levels in week 2 (p = 0.010), however, this effect was not sustained. This transient hypoglycaemic effect may be due in part to a reduction in the rate of intestinal glucose absorption or an increase in peripheral glucose utilization as this is commonly observed in the rodent models of streptozotocin-induced diabetic models (25) . Further, several flavonoids including quercetin which are present in the leaves of P alliacea (20) have been shown to reduce intestinal glucose absorption (26) (27) (28) and one plausible explanation for the unsustained hypoglycaemic effect seen with our extract could be inefficient inhibition of the sugar transporter GLUT2 by these flavonoids (26) . Finally, in our positive control group, insulin maintained the expected glycaemic range by producing a significant reduction in blood glucose levels over the treatment period (p ≤ 0.042).
CONCLUSION
When viewed collectively, no significant hypoglycaemic profile was established for P alliacea. Furthermore, a hyperglycaemic effect was observed with the aqueous extract at high dose. These findings hold significant implications for the ethno-traditional use of P alliacea as a hypoglycaemic agent where it is used in an aqueous form. 
